At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Pembrolizumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Chemotherapy Plus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Non-Small-Cell Lung Cancer. Completed, enrolled 35 participants across 5 sites.
Detailed Summary
This is a single-arm phase II study of continuation immunotherapy with pembrolizumab following initial benefit (CR, PR, or SD ≥ 3 months) with a PD-1 or PD-L1 inhibitor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small-Cell Lung Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC, Big Ten Cancer Research Consortium
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartMar 2017
Primary CompletionDec 2021
Study CompletionMar 2022
TodayJul 2026
First PostedMar 20, 2017
Enrollment StartMar 20, 2017
Primary CompletionDec 14, 2021
Study CompletionMar 3, 2022
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 9.3 years ago
Interventions
Pembrolizumabdrug
Pembrolizumab 200mg IV every 21 days \+ Physician's choice chemotherapy with one of the following every 21 days: * Docetaxel 75mg/m2 IV * Pemetrexed 500mg/m2 IV (non-squamous only) * Gemcitabine 1000mg/m2 IV on days 1 and 8